Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Fraxiforte®:Viatris Pharma GmbH
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
B01AB06 - NadroparinATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
B01 - Antithrombotic Agents
B01A - Antithrombotic Agents
B01AB - Heparin Group

This group comprises heparin preparations, including products for non-therapeutic use, e.g. for rinsing of indwelling vein cannulas. Heparin sodium and heparin calcium are classified at the same 5th level, i.e. B01AB01. The low molecular weight heparins are classified at separate 5th levels.
Both human-derived and recombinant products of antithrombin III are classified in B01AB02.

The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U). The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients. Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.
The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).

B01AB06 - Nadroparin
 Panti Xa
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home